EMILY CUTSHALL: Open Payments
NPI 1558026153 · SEWELL, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,130 in 72 payments from 18 companies in 2025. Trend: 2023 $1,965 · 2024 $2,193 · 2025 $1,130
Food & beverage: $1,130
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 13 | $193 |
| ABBVIE INC. | 10 | $158 |
| GlaxoSmithKline, LLC. | 11 | $137 |
| Collegium Pharmaceutical, Inc. | 5 | $85 |
| Lundbeck LLC | 4 | $64 |
| Astellas Pharma US Inc | 4 | $64 |
| PFIZER INC. | 4 | $64 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $56 |
| Axsome Therapeutics, Inc. | 3 | $54 |
| Amgen Inc. | 3 | $51 |
Products named: VRAYLAR, TRELEGY ELLIPTA, Ozempic, Belbuca, REXULTI, Veozah, Rybelsus, XIFAXAN.
Industry payments across NJ — which companies pay providers there.
